

[Learn about the latest trends and studies and read insightful articles pertaining to Pharma research.](#)

[View Online](#)



MAY EDITION

The Pharma Focus

Quarterly



Your touchstone for the latest Pharma research

Welcome to the new issue of Pearson's quarterly newsletter, The Pharma Focus! Our Pharma team is dedicated to curating the most relevant content to help you stay informed about the Pharma research industry. This edition features updates from the Pharma research industry, a featured webinar with our partners at Biopharma Dive, pertinent and timely articles, and research that utilizes many of our own widely used assessments.



KOL SPOTLIGHT

WEBINAR RECORDING:

Finding the best metrics for pediatric neurogenetic trial

Presented by: Dr. Elsa Shapiro, Dr. Julie Eisengart, and Dr. Paul Harmatz

In our recent webinar, Drs. Shapiro, Eisengart, and Harmatz discussed the neurogenetic illnesses that influence brain function in up to 3 percent of children, and the difficulty finding instruments sensitive enough to identify changes in their developmental skills.

Watch the recording and gain more insight into the difficulties associated with therapy in these trial settings.

WATCH ON-DEMAND →

The Pharma Guide

When every moment counts, having the right resources at the ready is imperative. We've put together a helpful Guide to help you plan your Pharma journey. Keep it handy and use it as a reference for commonly asked questions, pertinent resources, featured research, available COAs, thought leadership articles, and GSV information.

GET THE GUIDE →

Finnish localization case study

How a partner collaboration determined an effective multifaceted translation approach

Over the past decade, the Bayley Scales, an assessment tool that measures the developmental status of children aged 1-42 months, have been used as an outcome in 145 clinical trials. 6.21% of trials have found sites in Finno-Ugric nations, including Estonia, Finland, and Hungary.

In 2023, Pearson and Lionbridge faced challenges with 1 of the 13 target languages: Finnish - Finland (fiFI). Finno-Ugric languages differ from English in terms of gendered and possessive pronouns, as well as verb tense forms.

Learn more about how an interdisciplinary team created a translation that preserves instrument validity, worldwide reach, and the cultural context of the Finnish language by reading the case study.

READ THE BLOG →



PHARMA FOCUS FEATURED
ARTICLES

See how our clinical outcome assessments (COAs) are being used in the field.

Associations between Mediterranean Diet adherence, quality of life, and mental health in patients with multiple sclerosis: a cross-sectional study

In light of various sociodemographic, anthropometric, and lifestyle factors, the current study aims to assess the possible effects of the Mediterranean Diet (MD) on disease disability, quality of life, physical activity, depressive symptomatology, using the **Beck Depression Inventory[®], Second Edition (BDI[®]-2)**, and blood biochemical parameters related to nutritional status in multiple sclerosis (MS) patients. This cross-sectional study involved 558 MS persons between the ages of 18 and 64.

The current study discovered that increased MD adherence may lessen the effects of the disease, improving the quality of life and mental health of people with MS.

READ THE ARTICLE →

Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors

Children who survive brain tumors frequently experience neurocognitive impairments. Single nucleotide polymorphism (SNP) screening in DNA repair genes may help identify adolescents receiving radiation therapy for brain malignancies who are more vulnerable to side effects and neurocognitive impairments from the

treatment. This study utilizes the **Wechsler Intelligence Scale for Children®** to measure IQs.

SNPs may be able to predict poor neurocognitive outcomes in children who have survived brain tumors. Better treatment stratification and early cognitive therapies may be possible with improved identification of children at risk of treatment-related neurocognitive impairments.


READ THE ARTICLE →

Efficacy and safety of transcranial direct current stimulation over the left dorsolateral prefrontal cortex in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, triple-blinded, sham-controlled, crossover trial

Despite medication therapy for Attention-Deficit/Hyperactivity Disorder (ADHD) being shown to be effective, some people continue to struggle socially and academically. Furthermore, the incidence of serious adverse effects may make the usage of psychotropic drugs unsustainable. Transcranial Direct Current Stimulation (tDCS), a non-invasive brain stimulation technology, has shown promising results in treating ADHD.

This was a triple-blind, randomized, sham-controlled, crossover clinical trial that sought to examine the efficacy and safety of tDCS on the performance of children and adolescents with ADHD in neuropsychological tasks including visual attention, visual and verbal working memory, and inhibitory control. Subjects were also assessed before and after tDCS using the **Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)** Digit Span subtest, the **Developmental Neuropsychological Assessment®**, **Second Edition (NEPSY®-II)** Inhibiting Response (IR) subtest, and the Corsi Block-Tapping Task.

READ THE ARTICLE →



PUBLISHED RESEARCH

The Pharma research page

Visit the Pharma Research page to discover a curated list of peer-reviewed publications spanning several clinical areas in the pharma industry, Growth Scale Value (GSVs) Reports, and the latest Pharma blog posts.

All featured research is open access, so any articles you select are available to read, download, and share.

TAKE ME TO THE RESEARCH →



MEET OUR TEAM

How can our team support you?

For more than 80 years, Pearson has been at the forefront of developing the leading clinical and educational assessments that are used in many of today's research projects.

We've continued building on each decade of experience and user feedback, and as a result, today's robust COA portfolio includes **reliable**, **valid**, and **sensitive tools** used by pharmaceutical companies, biotech companies, and contract research organizations (CROs) conducting clinical research.



Lynsey Psimas,
PhD
Director of
Business
Development



Paul Williams,
PsyD
Account Manager



Jarett Lehner
Account Manager



Katrina Bengtson
Account Manager

[Reach out to our Pharma team](#) to start the conversation.



800-627-7271 | PearsonAssessments.com

Copyright © %%xyyear%% Pearson Education, Inc. or its affiliates. All rights reserved. Pearson, Beck, NEPSY, and WISC are trademarks, in the US and/or other countries, of Pearson plc

C9217 MJL 05/24